Abstracts tagged "rheumatoid arthritis (RA) and syk"

Abstract Number: 1528 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of MK-8457, a Novel SYK Inhibitor for the Treatment of Rheumatoid Arthritis in Two Randomized, Controlled, Phase 2 Studies
Ronald van Vollenhoven¹, S. B. Cohen², Philip J. Mease³, Charles G. Peterfy⁴, Wolfgang Spieler⁵, Judith Boice⁶, Sean Curtis⁷, Qing Li⁷, Ruji Yao⁸, Richard Baumgartner⁷ and Holly Weng⁸, ¹Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Metroplex Clinical Research Center, Dallas, TX, ³University of Washington, Seattle, WA, ⁴Spire Sciences LLC, Boca Raton, FL, ⁵Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁶Merck Research Laboratories, Whitehouse Station, NJ, ⁷Merck & Co., Inc, Whitehouse Station, NJ, ⁸Merck & Co., Inc., Whitehouse Station, NJ
Background/Purpose: Novel, targeted small-molecular medications are needed in the treatment of rheumatoid arthritis (RA). MK-8457 is a novel inhibitor of spleen tyrosine kinase (SYK)…
Abstract Number: 1500 • 2014 ACR/ARHP Annual Meeting
Preclinical and Clinical Characterization of MK-8457, a Selective Spleen Tyrosine Kinase and Zeta-Chain-Associated Protein Kinase 70 Inhibitor, in Normotensive and Hypertensive Cardiovascular Models
Hani Houshyar¹, Alan Bass², Judith Boice³, Michael Ellis⁴, Patrick Fanelli⁵, Tomoko Freshwater⁶, Jane Guo⁷, Kimberly Hoagland⁵, Janet Kerr⁵, Alan Northrup⁴, Mathew Maddess⁸, Richard Miller⁹, Marcella Ruddy¹⁰, Stella Vincent¹¹, Jayanthi Wolf⁵, Haoling Weng³, Gloria Zingaro⁵ and Gene Marcantonio³, ¹33 Avenue Louis Pasteur, Merck & Co., Boston, MA, ²Safety Assessment, Merck & Co., Boston, MA, ³Merck & Co., Whitehouse Station, NJ, ⁴Medicinal Chemistry, Merck & Co., Boston, MA, ⁵Merck & Co., West Point, PA, ⁶PPDM Early Stage, Merck & Co., Rahway, NJ, ⁷Immunology, Merck & Co., Boston, MA, ⁸Discovery Process Chemistry, Merck & Co., Boston, MA, ⁹Biochemistry & Biophysics, Merck & Co., Boston, MA, ¹⁰Merck & Co., Boston, MA, ¹¹PPDM Preclinical ADME, Merck & Co., Boston, MA
Background/Purpose: Spleen Tyrosine Kinase (SYK) and Zeta-chain-associated protein kinase 70 (ZAP70) are non-receptor protein kinases that bind phosophorylated receptor tyrosine-based activation motifs, critical in immune…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].